"Life doesn’t stop outside of cancer. Every patient has physical, emotional and spiritual needs. I want patients to know that if it’s important to them, it’s important to us," says Tori McClosky. Learn about her dedication to our patients: https://bit.ly/4bJ2hbZ #EndCancer
MD Anderson Cancer Center
Hospitals and Health Care
Houston, TX 218,885 followers
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Our mission: #EndCancer
About us
The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. MD Anderson provides cancer care at several convenient locations throughout the Greater Houston Area and collaborates with community hospitals and health systems nationwide through MD Anderson Cancer Network®. U.S. News & World Report's "Best Hospitals" survey has ranked MD Anderson the nation's top hospital for cancer care. Every year since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals. The recognition reflects the passion of our 21,000 extraordinary employees and 1,000 volunteers for providing exceptional care to our patients and their families, and for realizing our mission to #EndCancer. You can view all of our career opportunities at careers.mdanderson.org.
- Website
-
http://MDAnderson.org
External link for MD Anderson Cancer Center
- Industry
- Hospitals and Health Care
- Company size
- 10,001 employees
- Headquarters
- Houston, TX
- Type
- Educational
- Founded
- 1944
- Specialties
- Cancer, hospital, healthcare, oncology, research, doctor, health, wellness, medicine, education, education, science, health, clinical trials, nursing, cancer care, cancer research, training, fellowship, cancer education, cancer prevention, cancer treatment, and science and technology
Locations
Employees at MD Anderson Cancer Center
-
Guy Lipof
Data Science, AI, Executive, Healthcare & Life Sciences
-
Opral Wisham
QA Analyst V at Devon Energy
-
Ferran Prat Escude
Senior VP, Research Administration and Industry Relations at MD Anderson Cancer Center
-
Helio Dimas Nogueira
Executive Director - Project Management Officer, Technology & Innovation
Updates
-
We’re collaborating with Summit Therapeutics, Inc. to discover more opportunities for ivonescimab, including several tumor types outside of its current development plan. MD Anderson will lead multiple clinical trials to evaluate the safety and potential clinical benefit of ivonescimab. Learn more. #CancerResearch #EndCancer
MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
mdanderson.org
-
A study of adolescent and young adult cancer survivors led by our Dr. Michelle Hildebrandt shows that a patient’s physical and mental health-related quality of life at the time of diagnosis was a predictor of their overall survival. Read about this and more research from MD Anderson. #CancerResearch #EndCancer
MD Anderson Research Highlights for July 24, 2024
mdanderson.org
-
MD Anderson is proud to be named one of America's Best Employers for Women by Forbes. See the full list here: https://bit.ly/3ShMAQM #EndCancer
-
-
“Being coached is a unique gift and an opportunity. You just have to be open to hearing that you need to do things in a different way,” says our Frances Snipes. Learn about MD Anderson's culture of coaching. #EndCancer
How coaching is elevating MD Anderson’s workforce
mdanderson.org
-
To expand our oncology efforts around the world, MD Anderson has signed a memorandum with the Ministry of Health of Zambia to enhance cancer prevention, treatment, research and education. Learn more. #EndCancer
MD Anderson expands global oncology efforts through new agreement with Zambia Ministry of Health
mdanderson.org
-
Young people with Ewing’s sarcoma, a highly aggressive bone cancer, have few treatment options and a poor prognosis for recurrence. A Phase I/II clinical trial co-led by Joseph Ludwig, M.D., investigates the ability of the novel small molecule TK216 to disrupt the oncogenic fusion protein EWS-FLI1 in previously treated, relapsed/recurrent Ewing's sarcoma. Findings suggest a potential path forward to investigate prospective drug candidates that target the pathognomonic fusion protein in Ewing's sarcoma and other sarcoma subtypes. Learn more about this and other new research from MD Anderson. #CancerResearch #EndCancer
MD Anderson Research Highlights for July 11, 2024
mdanderson.org
-
We’ve named our ninth cohort of Andrew Sabin Family Fellows. These fellows’ innovative research encompasses a variety of fields, including immunology, radiation oncology and biostatistics. Learn more about them. George Calin Peter Pisters #CancerResearch #EndCancer
MD Anderson’s Andrew Sabin Family Fellows welcomes 2024 cohort
mdanderson.org
-
MD Anderson is honored to again be ranked No. 1 in the nation for cancer care in U.S. News & World Report's “Best Hospitals” annual survey. We are deeply grateful to all who have helped make this recognition possible: our teammates, trainees, students, donors, volunteers, advocates and the patients and families we are honored to serve. Working together, we continue to move forward in our mission to end cancer. “This ranking reflects our relentless commitment to excellence in patient care, research, prevention and education,” says Dr. Peter Pisters, president of MD Anderson. “Together, we are making significant strides toward a future free from cancer.” Read more: https://bit.ly/3W7UptL #EndCancer
-
-
"MD Anderson was the right choice. My experiences as a patient have only confirmed my confidence in what we do. It makes me super proud to work here," says four-time cancer survivor and employee Angela Harris. Read her story. #HealthCare #EndCancer
4-time cancer survivor and employee: Why I chose MD Anderson for my treatment
mdanderson.org